Abstract 1164P
Background
The standard approach for managing locally advanced rectal cancer includes preoperative neoadjuvant chemoradiotherapy followed by curative surgery, a regimen acknowledged for substantially enhancing local control rates. Nevertheless, the benefits of perioperative radiotherapy in treating rectal neuroendocrine carcinoma merit further investigation. This study explores the impact of preoperative neoadjuvant radiotherapy on the feasibility of sphincter-preserving surgery and on the overall survival rates in patients with locally advanced rectal neuroendocrine carcinoma.
Methods
Data from patients diagnosed with locally advanced (T3/T4 or N+) neuroendocrine carcinoma who underwent curative surgery from 2004 to 2019 were collected using the SEER database. We assessed clinical characteristics, treatment information, and overall survival rates. Statistical comparisons of categorical variables were performed using the Chi-square test or Fisher's exact test. Survival outcomes were analyzed using the Kaplan-Meier method.
Results
Of the 44 patients identified, 14 underwent preoperative neoadjuvant radiotherapy. Patients with a T-stage above T3 (42.9% vs. 12.5%, P = 0.049) and those without lymph node metastasis (87.5% vs. 19.4%, P < 0.001) were more likely to receive perioperative radiotherapy. The probability of performing sphincter-preserving surgery was notably lower in patients treated with neoadjuvant radiotherapy (57.1% vs. 93.3%, P = 0.008). Additionally, survival analysis indicated no significant relationship between neoadjuvant radiotherapy and overall survival (HR 1.298,95% CI:0.519-3. 244, P =0. 577).
Conclusions
Neoadjuvant radiotherapy prior to surgery did not improve the likelihood of performing sphincter-preserving procedures in patients with locally advanced rectal neuroendocrine carcinoma, nor did it significantly impact overall survival. Further research involving larger sample sizes is required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work, the author(s) used ChatGPT for editorial assistance in order to optimize content expression. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
W. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
961P - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve oncologic outcomes in diabetic patients with hepatocellular carcinoma (HCC): A nationwide database study
Presenter: Chien-Huai Chuang
Session: Poster session 17
962P - Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort
Presenter: Pablo Azcue
Session: Poster session 17
963P - Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab + rivoceranib (cam+rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Presenter: Andrew Moon
Session: Poster session 17
964P - Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)
Presenter: Markus Peck Radosavljevic
Session: Poster session 17
967P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster session 17
968P - HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trial
Presenter: Xiaodong Wang
Session: Poster session 17
969P - Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
Presenter: Pasquale Lombardi
Session: Poster session 17
970P - Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world study
Presenter: Yangxun Pan
Session: Poster session 17
Resources:
Abstract
971P - Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world study
Presenter: binghua dai
Session: Poster session 17